These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 22068250)

  • 1. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
    Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
    Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
    Armato JP; DeFronzo RA; Abdul-Ghani M; Ruby RJ
    Lancet Diabetes Endocrinol; 2018 Oct; 6(10):781-789. PubMed ID: 30224284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
    RISE Consortium
    Diabetes Care; 2014; 37(3):780-8. PubMed ID: 24194506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the pharmacotherapy options for treating prediabetes?
    Daniele G; Abdul-Ghani M; DeFronzo RA
    Expert Opin Pharmacother; 2014 Oct; 15(14):2003-18. PubMed ID: 25139488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
    Ionut V; Woolcott OO; Mkrtchyan HJ; Stefanovski D; Kabir M; Iyer MS; Liu H; Castro AV; Wu Q; Broussard JL; Kolka CM; Asare-Bediako I; Bergman RN
    PLoS One; 2016; 11(7):e0158703. PubMed ID: 27398720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
    Tripathy D; Cobb JE; Gall W; Adam KP; George T; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Reaven PD; Musi N; Ferrannini E; DeFronzo RA
    J Clin Endocrinol Metab; 2015 May; 100(5):1855-62. PubMed ID: 25603459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
    Jensterle M; Goricar K; Janez A
    Endocr Res; 2017 Nov; 42(4):261-268. PubMed ID: 28323503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle.
    Alvarez-Canales MFL; Salazar-López SS; Farfán-Vázquez D; Martínez-López YE; González-Mena JN; Jiménez-Ceja LM; Vargas-Ortiz K; Evia-Viscarra ML; Montes de Oca-Loyola ML; Folli F; Aguilar-García A; Guardado-Mendoza R
    Sci Rep; 2021 Apr; 11(1):8750. PubMed ID: 33888772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
    Samms RJ; Cheng CC; Fourcaudot M; Heikkinen S; Khattab A; Adams J; Cersosimo E; Triplitt C; Puckett C; Tsintzas K; Adams AC; Abdul-Ghani MA; DeFronzo RA; Norton L
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E123-E132. PubMed ID: 35723225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
    Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
    Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
    Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
    Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A refined-JinQi-JiangTang tablet ameliorates prediabetes by reducing insulin resistance and improving beta cell function in mice.
    Gao LH; Liu Q; Liu SN; Chen ZY; Li CN; Lei L; Sun SJ; Li LY; Liu JL; Shen ZF
    J Ethnopharmacol; 2014; 151(1):675-85. PubMed ID: 24286962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
    Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
    Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide.
    Schwartz S
    Curr Med Res Opin; 2008 Nov; 24(11):3009-22. PubMed ID: 18828960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of β-cell function: the key to diabetes prevention.
    DeFronzo RA; Abdul-Ghani MA
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2354-66. PubMed ID: 21697254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Insulin Resistance and β-Cell Dysfunction Between the Young and the Elderly in Normal Glucose Tolerance and Prediabetes Population: A Prospective Study.
    Chen G; Shi L; Cai L; Lin W; Huang H; Liang J; Li L; Lin L; Tang K; Chen L; Lu J; Bi Y; Wang W; Ning G; Wen J
    Horm Metab Res; 2017 Feb; 49(2):135-141. PubMed ID: 27459384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.